Rhythm Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Rhythm Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | ||||||||||||||||||||||||||||||||
| product revenue | 48,502,000 | 37,718,000 | 41,830,000 | 33,251,000 | 29,078,000 | 25,967,000 | 24,234,000 | 22,504,000 | 19,221,000 | 11,469,000 | 8,790,000 | 4,284,000 | 2,312,000 | 1,498,000 | 1,817,000 | 1,028,000 | 274,000 | 35,000 | ||||||||||||||
| license revenue | -5,014,000 | 6,754,000 | ||||||||||||||||||||||||||||||
| total revenues | 48,502,000 | 32,704,000 | 41,830,000 | 33,251,000 | 29,078,000 | 25,967,000 | 24,234,000 | 22,504,000 | 19,221,000 | |||||||||||||||||||||||
| costs and expenses: | ||||||||||||||||||||||||||||||||
| cost of sales | 5,543,000 | 3,648,000 | 3,787,000 | 3,828,000 | 2,947,000 | 2,807,000 | 3,233,000 | 2,412,000 | 2,236,000 | 1,421,000 | 1,028,000 | 497,000 | 378,000 | 230,000 | 236,000 | 222,000 | 137,000 | 4,000 | ||||||||||||||
| gross profit | ||||||||||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||||||||
| qoq | ||||||||||||||||||||||||||||||||
| gross margin % | ||||||||||||||||||||||||||||||||
| research and development | 42,308,000 | 36,973,000 | 41,168,000 | 37,931,000 | 30,194,000 | 128,665,000 | 29,892,000 | 33,570,000 | 33,543,000 | 37,945,000 | 23,548,000 | 21,116,000 | 31,456,000 | 32,510,000 | 31,574,000 | 27,539,000 | 25,104,000 | 19,911,000 | 21,954,000 | 22,995,000 | 22,997,000 | 22,504,000 | 24,809,000 | 26,572,000 | 35,308,000 | 22,761,000 | 18,762,000 | 10,705,000 | 8,584,000 | 12,286,000 | -16,218,106 | 5,971,000 |
| selling, general, and administrative | 45,947,000 | 39,087,000 | 38,130,000 | 35,377,000 | 36,415,000 | 34,382,000 | 32,374,000 | 30,475,000 | 30,046,000 | 24,634,000 | 26,317,000 | 21,938,000 | 22,328,000 | 21,449,000 | 20,996,000 | 17,507,000 | 15,465,000 | 14,518,000 | 13,119,000 | 11,289,000 | 8,921,000 | 12,796,000 | 9,415,000 | 10,535,000 | 8,841,000 | 7,759,000 | 8,389,000 | 8,539,000 | 6,437,000 | 4,715,000 | ||
| total costs and expenses | 93,798,000 | 79,708,000 | 83,085,000 | 77,136,000 | 69,556,000 | 165,854,000 | 65,499,000 | 66,457,000 | 65,825,000 | 64,000,000 | 50,893,000 | 43,551,000 | 54,162,000 | 54,189,000 | 52,806,000 | 45,268,000 | 40,706,000 | 34,433,000 | ||||||||||||||
| income from operations | -45,296,000 | -47,004,000 | -41,255,000 | -43,885,000 | -40,478,000 | -139,887,000 | -41,265,000 | -43,953,000 | -46,604,000 | -52,531,000 | -42,103,000 | -39,267,000 | -45,096,000 | -52,691,000 | -50,989,000 | -44,240,000 | -40,432,000 | -34,398,000 | -35,073,000 | -34,284,000 | -31,918,000 | -35,300,000 | -34,224,000 | -37,107,000 | -44,149,000 | -30,520,000 | -27,151,000 | -19,244,000 | -15,021,000 | -17,001,000 | 21,396,588 | -8,286,000 |
| yoy | 11.90% | -66.40% | -0.02% | -0.15% | -13.14% | 166.29% | -1.99% | 11.93% | 3.34% | -0.30% | -17.43% | -11.24% | 11.54% | 53.18% | 45.38% | 29.04% | 26.67% | -2.56% | 2.48% | -7.61% | -27.70% | 15.66% | 26.05% | 92.82% | 193.92% | 79.52% | -226.89% | 132.25% | ||||
| qoq | -3.63% | 13.94% | -5.99% | 8.42% | -71.06% | 239.00% | -6.12% | -5.69% | -11.28% | 24.77% | 7.22% | -12.93% | -14.41% | 3.34% | 15.26% | 9.42% | 17.54% | -1.92% | 2.30% | 7.41% | -9.58% | 3.14% | -7.77% | -15.95% | 44.66% | 12.41% | 41.09% | 28.11% | -11.65% | -179.46% | -358.23% | |
| operating margin % | ||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||
| other income | 1,576,000 | -644,000 | -195,000 | 1,088,000 | 302,000 | 524,000 | 559,000 | -159,000 | -17,000 | -27,000 | -92,500 | -370,000 | 100,000,000 | |||||||||||||||||||
| gain on settlement of forward contract | 8,900,000 | |||||||||||||||||||||||||||||||
| interest expense | -5,817,000 | -5,409,000 | -5,447,000 | -5,242,000 | -4,603,000 | -4,755,000 | -4,550,000 | -3,149,000 | -3,303,000 | -3,061,000 | -3,011,000 | -2,144,000 | ||||||||||||||||||||
| interest income | 3,242,000 | 3,639,000 | 3,515,000 | 4,054,000 | 4,097,000 | 3,046,000 | 3,819,000 | 3,466,000 | 3,221,000 | 3,440,000 | 3,041,000 | 920,000 | 95,000 | -73,000 | 134,000 | 138,000 | 21,000 | 154,000 | 176,000 | 466,000 | 801,000 | 1,136,000 | 1,268,000 | 1,104,000 | 1,353,000 | 1,546,000 | 1,644,000 | 1,558,000 | 609,000 | 542,000 | -113,434 | 51,000 |
| total other (expense) | -999,000 | -2,414,000 | ||||||||||||||||||||||||||||||
| income before income taxes | -46,295,000 | -49,418,000 | -43,382,000 | -43,985,000 | -31,782,000 | -141,072,000 | ||||||||||||||||||||||||||
| benefit from income taxes | 337,000 | 80,000 | 479,000 | 300,000 | 196,000 | 368,000 | 1,997,250 | -8,995,000 | -5,022,000 | 22,006,000 | ||||||||||||||||||||||
| net income | -46,632,000 | -49,498,000 | -43,292,000 | -43,641,000 | -32,261,000 | -141,372,000 | -41,633,000 | -44,163,000 | -46,703,000 | -52,179,000 | -42,493,000 | -40,861,000 | -45,001,000 | -52,764,000 | -42,866,000 | -35,107,000 | -35,389,000 | 43,750,000 | -34,897,000 | -33,818,000 | -31,117,000 | -34,164,000 | ||||||||||
| yoy | 44.55% | -64.99% | 3.98% | -1.18% | -30.92% | 170.94% | -2.02% | 8.08% | 3.78% | -1.11% | -0.87% | 16.39% | 27.16% | -220.60% | 22.84% | 3.81% | 13.73% | -228.06% | ||||||||||||||
| qoq | -5.79% | 14.34% | -0.80% | 35.27% | -77.18% | 239.57% | -5.73% | -5.44% | -10.49% | 22.79% | 3.99% | -9.20% | -14.71% | 23.09% | 22.10% | -0.80% | -180.89% | -225.37% | 3.19% | 8.68% | -8.92% | |||||||||||
| net income margin % | ||||||||||||||||||||||||||||||||
| accrued dividends on convertible preferred stock | -1,349,000 | -1,322,000 | -1,339,000 | -1,329,000 | -1,302,000 | |||||||||||||||||||||||||||
| net income attributable to common stockholders | -47,981,000 | -50,820,000 | -44,631,000 | -44,970,000 | -33,563,000 | -32,956,000 | -36,003,000 | -42,796,000 | -28,974,000 | -25,507,000 | -17,686,000 | -14,412,000 | -16,459,000 | 26,925,418 | -11,429,000 | |||||||||||||||||
| net income per share | -0.75 | -0.81 | -0.72 | -0.73 | -0.55 | -2.35 | -0.7 | -0.76 | -0.82 | -0.92 | -0.74 | -0.79 | -0.86 | -0.7 | -0.79 | -0.77 | -0.71 | -0.78 | -0.73 | -1.04 | -1.24 | -0.84 | ||||||||||
| | ||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 63,684,359 | 63,059,165 | 60,995,204 | 61,219,918 | 61,011,824 | 60,143,558 | 57,673,128 | 57,874,960 | 56,867,662 | 56,708,975 | 52,120,701 | 51,400,922 | 49,600,294 | 50,246,303 | 44,127,220 | 44,142,334 | 44,098,860 | 44,049,843 | 36,422,450 | 34,541,765 | 34,452,661 | 34,417,189 | 31,004,047,000 | 34,256,519,000 | 27,960,664,000 | 27,284,140,000 | 13,267,960 | 6,404,254,000 | ||||
| other comprehensive loss: | ||||||||||||||||||||||||||||||||
| foreign currency translation adjustment | -2,104 | -2 | 977 | -602 | -302 | -71 | -189 | 76 | -48 | 21 | ||||||||||||||||||||||
| unrealized (loss), net on marketable securities | -93 | -10 | ||||||||||||||||||||||||||||||
| comprehensive loss | -50,178 | -50,832 | -44,067 | -44,957 | -33,999 | -141,687 | -41,386 | -44,262 | -46,711 | -52,093 | -42,246 | -40,294 | -42,760 | -35,107 | -35,086 | -34,210 | -30,550 | -34,101 | ||||||||||||||
| total other income | -2,127,000 | -100,000 | 8,696,000 | -1,185,000 | -172,000 | 158,000 | -99,000 | 352,000 | -390,000 | -1,594,000 | 95,000 | -73,000 | 134,000 | 138,000 | 21,000 | 100,154,000 | 176,000 | 466,000 | 801,000 | 1,136,000 | ||||||||||||
| benefit for income taxes | 109,000 | -344,000 | ||||||||||||||||||||||||||||||
| unrealized gain, net on marketable securities, net of tax | -412 | 615 | -134 | |||||||||||||||||||||||||||||
| unrealized gain, net on marketable securities | -244 | 436 | -175 | 40 | 65 | 247 | 267 | |||||||||||||||||||||||||
| income before taxes | -35,669,250 | -43,795,000 | -34,656,500 | -40,861,000 | -45,001,000 | -52,764,000 | -4,689,250 | -44,102,000 | -40,411,000 | 65,756,000 | ||||||||||||||||||||||
| reclassification of losses on rarestone equity into net income | 300 | |||||||||||||||||||||||||||||||
| (benefit from) benefit from income taxes | ||||||||||||||||||||||||||||||||
| net income per share | -0.75 | -0.81 | -0.72 | -0.73 | -0.55 | -2.35 | -0.7 | -0.76 | -0.82 | -0.92 | -0.74 | -0.79 | -0.86 | -0.7 | -0.79 | -0.77 | -0.71 | -0.78 | -0.73 | -1.04 | -1.24 | -0.84 | ||||||||||
| basic | -0.89 | -1.05 | -0.7 | 0.92 | ||||||||||||||||||||||||||||
| diluted | -0.89 | -1.05 | -0.7 | 0.9 | ||||||||||||||||||||||||||||
| weighted-average common shares outstanding | ||||||||||||||||||||||||||||||||
| basic | 50,398,003 | 50,326,627 | 50,209,484 | 47,638,565 | ||||||||||||||||||||||||||||
| diluted | 50,398,003 | 50,326,627 | 50,209,484 | 48,501,697 | ||||||||||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||||
| unrealized income on marketable securities and other long-term assets | -277 | |||||||||||||||||||||||||||||||
| comprehensive income | -45,278 | -53,392 | -35,310 | 43,643 | ||||||||||||||||||||||||||||
| unrealized loss on marketable securities | -628 | |||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | 106 | 79 | -107 | -189 | -392 | 567 | 63 | |||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||
| total operating expenses | 35,073,000 | 34,284,000 | 31,918,000 | 35,300,000 | 34,224,000 | 37,107,000 | 44,149,000 | 30,520,000 | 27,151,000 | 19,244,000 | 15,021,000 | 17,001,000 | -21,396,588 | 8,286,000 | ||||||||||||||||||
| total other income: | 1,000,750 | 1,104,000 | 1,353,000 | 1,546,000 | 1,644,000 | 1,558,000 | 609,000 | 542,000 | 1,747,703 | -1,730,000 | ||||||||||||||||||||||
| net income and comprehensive loss | -26,943,250 | -36,003,000 | -42,796,000 | -28,974,000 | -25,507,000 | -17,686,000 | -14,412,000 | -16,459,000 | 23,144,291 | -10,016,000 | ||||||||||||||||||||||
| revaluation of series a investor instrument and series a investor right/obligation | ||||||||||||||||||||||||||||||||
| net income attributable to common stockholders per common share, basic and diluted | -760 | -520 | -520 | -600 | 3,017.17 | -1,780 | ||||||||||||||||||||||||||
| general and administrative | 1,297,000 | 2,315,000 | ||||||||||||||||||||||||||||||
| revaluation of series a investor instrument | -465,750 | -1,781,000 |
We provide you with 20 years income statements for Rhythm Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Rhythm Pharmaceuticals stock. Explore the full financial landscape of Rhythm Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Rhythm Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.